Gain Therapeutics, Inc.

NASDAQ:GANX

Biotechnology

Healthcare
$1.18 +3.09%

+$0.06 today

Market cap
$50.33M
Beta
0.16
P/E (TTM)
-3.6
EPS (TTM)
-$0.50
52W Low $1.41High $4.34

Volume 4.26M

Average 0.64M

GANX Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Gain Therapeutics, Inc.NASDAQ: GANX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $21.3K rose 3.1% year over year, behind the +12.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 24.6% from the prior quarter. Over 3 fiscal years it compounded at +13.6% a year.

Context

  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.1% toward the trailing-twelve-month pace of +12.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$21.3K-24.6% QoQ
Last fiscal yearDec 2025
$94.05K+11.9% YoY
LTMMar 2026
$94.69K+12.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.1%——
1 year+11.9%——
3-year CAGR+13.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
94.05K USD
Year-over-year change
+11.9%
4-year CAGR
+57.0%

Depreciation & Amortization vs competitors

How GANX compares with its peers on the latest reported figures

  • GANX's LTM Mar 2026 depreciation & amortization of $94.69K is the smallest of the 9 companies compared; the peer median is $2.23M.
  • Its year-over-year change of +12.5% is the 3rd highest of 8, against a peer median of -10.2%.
  • Over three fiscal years its annual growth of +13.6% compares with a peer median of -15.6%.
GANX Competitors Peer median
Depreciation & Amortization for GANX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OSTXOS Therapies IncorporatedLTM Mar 2026$363.33M +106428.1%+7569.0%—
FBIOFortress Biotech, Inc.LTM Mar 2026$5.17M +4.4%-20.7%7.8%
ACETAdicet Bio, Inc.LTM Mar 2026$3.86M -37.8%-3.9%—
TCRXTScan Therapeutics, Inc.LTM Mar 2026$2.88M -18.4%-17.7%31.5%
XBITXBiotech Inc.LTM Mar 2026$1.58M -10.2%-13.6%—
ADAGAdagene Inc.LTM Jun 2024$515.94K —-25.9%63.2%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$305K +6000.0%+229.4%13.3%
NTRBNutriband Inc.LTM Apr 2026$170.49K -37.6%-19.3%9.5%
GANXGain Therapeutics, Inc.LTM Mar 2026$94.69K +12.5%+13.6%—
Peer median (excluding GANX) $2.23M-10.2%-15.6%13.3%

Competitors are the stored peer set for GANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.89M)(17.59M)(22.27M)(20.41M)(20.16M)
Depreciation & Amortization15.48K64.17K83.58K84.07K94.05K
Deferred Income Tax00000
Stock-Based Compensation839.37K1.53M3.26M2.39M1.8M
Change in Working Capital(329.78K)1.51M442.23K(1.08M)(1.01M)
Accounts Receivables(63.35K)3.63K000
Inventory00000
Accounts Payables(521.39K)1.07M(643.16K)274.89K(468.61K)
Other Working Capital254.96K444.52K1.09M(1.36M)(537.91K)
Other Non-Cash Items999.87K(206.86K)(383.19K)143.52K804.94K
Operating Cash Flow(12.37M)(14.69M)(18.87M)(18.87M)(18.47M)
Capital Expenditures(94.21K)(118.95K)(15.36K)(22.49K)0
Acquisitions (Net)00000
Purchases of Investments0(17.74M)(1.96M)00
Sales of Investments03.08M12.19M5M0
Other Investing Activities00000
Investing Cash Flow(94.21K)(14.77M)10.22M4.98M0
Debt Repayment(21.95K)(78.77K)(89.07K)(90.88K)(96.5K)
Common Stock Issued42.63M012.73M13.21M28.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(841.27K)00(109.36K)0
Financing Cash Flow41.77M(78.77K)12.64M13.01M28.45M
Effect of Forex Changes100.78K(23.8K)488.4K(527.17K)469.43K
Net Change in Cash29.41M(29.57M)4.49M(1.41M)10.46M
Free Cash Flow(12.46M)(14.81M)(18.88M)(18.9M)(18.47M)

Gain Therapeutics, Inc.

NASDAQ:GANX

Intrinsic Alpha fair value

Locked

Current Price

$1.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.